With sales of CHF 135.4 million during the first six months of 2010, the Siegfried Group (SIX: SFZN) achieved a 12.4% jump over 2009 (15.4% in local currencies).

Active pharmaceutical ingredients (API) & intermediates earned CHF 103.9 million, a 14.5% increase over the previous year, while the ...

Cooperation with Bilfinger Berger Industrial Services AG and GWE GmbH

Newsletter 1/10

Part 1: Corporate News Download  PDFPart 2: Know-how: Siegfried's One Stop Shop for partners in the pharmaceutical industry. Download  PDFPart 3: Flyer Symposium (23/9/2010) Downlaod PDF

Siegfried has the right to supply at least 60% of Jazz Pharmaceutical’s worldwide requirements of sodium oxybate, the active pharmaceutical ingredient in Xyrem® (sodium oxybate) oral solution.

Siegfried issues mandatory convertible notes of 80 million Swiss francs

Mandatory convertible notes of Siegfried Holding AG – Successful advance

subscription offer secures maximum issue volume of CHF 80 million

Siegfried Holding AG in Zofingen (SIX: SFZN) has named Wolfgang Wienand, Ph.D., to Siegfried’s Executive Committee with responsibility for research and development.

Shareholders with questions should consult the custodian, broker or other intermediary through whom they hold their shares.

Please note:The advance subscription rights (the "Rights"), the Notes issuable upon exercise of the Rights and the registered shares of Siegfried Holding AG ...

At the annual general meeting of shareholders of Siegfried Holding AG (SIX: SFZN) of April

14, 2010 all motions submitted by the Board of Directors were approved, in particular the

creation of limited capital

Malcolm Perkins announces his resignation from Siegfried’s Board of Directors.

Siegfried Holding AG (SIX: SFZN) has received Malcolm Perkins’ resignation from its Board of Directors effective April 15, 2010, the day following the annual general meeting of shareholders.

The Board of Directors of Siegfried Holding AG (SIX:SFZN) will propose to the annual Shareholder’s Meeting on 14 April 2010 the appointment of Andreas Casutt, LL.M. to the Board for a term of three years.

Siegfried Holding AG announces changes in its shareholding structure:

Camellia plc, Siegfried Holding AG’s largest shareholder, informed the company that it sold its entire holding of 903,680 shares in Siegfried Holding AG to several independent investors. The investors include Rainer-Marc ...

The Siegfried Group achieved sales of CHF 283 million, a 2.2% decrease over the previous year. Sales of active ingredients

(Siegfried Actives) grew 15.3% to CHF 220.9 million.

The Siegfried Generics Division reported sales of CHF 62.1

million, a drop of 36%.

The Siegfried Group reports sales of CHF 283.0 million for the 2009 financial

year, a 2.2% decline when compared to the previous year. While sales of active

pharmaceutical ingredients (Siegfried Actives) rose by 15.3% to CHF 220.9 million, the Generics division sales fell by 36% to CHF 62.1 ...

Effective March 1, 2010, the Siegfried Group (SIX: SFZN) will introduce a functional

organization to replace its current two-division structure.

For the first nine months of the 2009 financial year, the Siegfried Group (SIX: SFZN) reported sales of 201.5 million Swiss francs, or 5.6% less than in the comparable period the previous year. Adjusted for a one-time royalty payment for a biogeneric drug in the 2008 financial year, the Siegfried ...

Newsletter 3/09

Part 1: Corporate News > Download PDF Part 2: Corporate Know-how: Customer Audits - Obligation or Opportunity > Download PDF

Siegfried opens state-of-the-art building for chemical and analytical development.

In the annual review of the best-designed and most informative annual reports for 2008, Bilanz Magazine rated Siegfried ahead of numerous well-known Swiss corporations.

Recession affects first six months – improved outlook for core business